Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VA Selects Aquilent For $2.7m Health IT Support Contracts
Aquilent has been selected by the Department of Veterans Affairs (VA) for two health IT support contracts valued around $2.7m. Under the terms of the contracts, Aquilent is
Aquilent has been selected by the Department of Veterans Affairs (VA) for two health IT support contracts valued around $2.7m. Under the terms of the contracts, Aquilent is
The company claims that these kits are the latest additions to the Applied Biosystems leading-edge portfolio of validated human identification workflow solutions, including genetic analyzers, reagent kits, PCR
US Patent and Trademark Office (USPTO) has issued a patent for the Champions Biotechnology’s (Champions) tubulin inhibitors, including its lead compound SG410. Reportedly, US Patent No. 7,595,326 entitled
OPKO Health has entered into a definitive agreement with Schering-Plough to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Reportedly, the lead product, Rolapitant recently completed
ICON has strengthened its Bioanalytical Sciences team following the acquisitions of Prevalere Life Sciences (Prevalere) and Veeda Laboratories (Veeda) with the appointment of Dr. Ray Briggs as vice
GlaxoSmithKline (GSK) has entered into a partnership with the UK Government, The Wellcome Trust and the East of England Development Agency (EEDA), to develop a new biotechnology science
FT4 Powder Rheometer from Freeman Technology is enabling organic chemists at Clarochem (Ireland), to incorporate some fundamental aspects of material science into their crystallization work. Reportedly, FT4 Powder
The US FDA has warned four companies to stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics (commonly known as narcotics) that are widely used to
Shire, the Irish drugmaker, has settled patent lawsuits with Novartis’ Sandoz unit that was attempting to market a generic version of its attention deficit hyperactivity disorder drug (ADHD)
Provectus Pharmaceuticals (Provectus) has completed patient accrual and initial treatment in its phase 2 trial of PH-10 for the treatment of plaque psoriasis. This marks the third phase